Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2017 Summary Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Cancer/Testis Antigen 1 is a protein encoded by CTAG1A gene is an antigen that is over expressed in many cancers but that is also expressed in normal ovary and testis tissues which makes it a good candidate for a cancer vaccine. Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 6 and 4 respectively. Similarly, the universities portfolio in Phase I stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Metastatic Melanoma, Soft Tissue Sarcoma, Lung Cancer, Metastatic Ovarian Cancer, Synovial Sarcoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Melanoma, Metastatic Breast Cancer, Myelodysplastic Syndrome, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Advanced Malignancy, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Bladder Cancer, Ewing Sarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Myxoid Liposarcoma, Neuroblastoma, Oligodendroglioma, Osteosarcoma, Rhabdomyosarcoma, Round Cell Liposarcoma, Sarcomas, Solid Tumor, Transitional Cell Cancer (Urothelial Cell Cancer) and Uterine Cancer. The latest report CancerTestis Antigen 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - The report reviews Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics and enlists all their major and minor projects - The report assesses Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Overview 7 Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 14 Products under Development by Universities/Institutes 19 Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Therapeutics Assessment 21 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Companies Involved in Therapeutics Development 25 Boehringer Ingelheim GmbH 25 Celldex Therapeutics Inc 26 GlaxoSmithKline Plc 27 Immune Design Corp 28 ImmunoFrontier Inc 29 Sanofi Pasteur SA 29 Scancell Holdings Plc 30 Vault Pharma Inc 30 Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drug Profiles 31 BI-1361849 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 CDX-1401 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 CMB-305 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 CMB-305 + G-100 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 CUE-102 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 CYN-101 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 G-305 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 GSK-2241658A - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 IMF-001 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 IMM-65 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 LV-305 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 SCIB-2 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 VCP-2292 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 VPI-111 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Dormant Products 56 Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Discontinued Products 59 Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Product Development Milestones 60 Featured News & Press Releases 60 Jun 26, 2017: Scancell Holdings Announces SCIB-2 Patent Granted in Europe 60 Jun 05, 2017: Immune Design Updates Positive Data from Lead Cancer Immunotherapy Program CMB305 at ASCO Annual Meeting 60 Jun 01, 2017: Immune responses from early study of novel sarcoma vaccine 62 May 17, 2017: New Clinical and Biomarker Data Validate Immune Design's CMB305 Program 63 Dec 05, 2016: Celldex Presents Data on CDX-1401 at the American Society of Hematology Annual Meeting 64 Oct 10, 2016: Scancell preparing SCIB2 for clinical study in lung cancer 64 Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate LV305 at ASCO 65 Jun 08, 2016: Immune Design Announces Updated Results For Immuno-oncology Product Candidate CMB305 At ASCO 66 Jun 04, 2016: Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma 66 Apr 21, 2016: Immune Design Announces Presentation on LV-305 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 68 Apr 18, 2016: Celldex Therapeutics Presents Poster on CDX-1401 at the AACR Annual Meeting 2016 68 Feb 09, 2016: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trial of CMB305 69 Jan 08, 2016: Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305 69 Nov 11, 2015: Immune Design Announces Start of Randomized Phase 2 Cancer Immunotherapy Combination Trial in Patients with Soft Tissue Sarcoma 70 Aug 12, 2015: Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration 70 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indications, H2 2017 11 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13 Number of Products under Development by Companies, H2 2017 14 Products under Development by Companies, H2 2017 15 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18 Number of Products under Investigation by Universities/Institutes, H2 2017 19 Products under Investigation by Universities/Institutes, H2 2017 20 Number of Products by Stage and Route of Administration, H2 2017 22 Number of Products by Stage and Molecule Type, H2 2017 24 Pipeline by Boehringer Ingelheim GmbH, H2 2017 25 Pipeline by Celldex Therapeutics Inc, H2 2017 26 Pipeline by GlaxoSmithKline Plc, H2 2017 27 Pipeline by Immune Design Corp, H2 2017 28 Pipeline by ImmunoFrontier Inc, H2 2017 29 Pipeline by Sanofi Pasteur SA, H2 2017 29 Pipeline by Scancell Holdings Plc, H2 2017 30 Pipeline by Vault Pharma Inc, H2 2017 30 Dormant Products, H2 2017 56 Dormant Products, H2 2017 (Contd..1), H2 2017 57 Dormant Products, H2 2017 (Contd..2), H2 2017 58 Discontinued Products, H2 2017 59
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
